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Carvedilol for Prevention of Restenosis After Directional
Coronary Atherectomy
Final Results of the European Carvedilol Atherectomy Restenosis
(EUROCARE) Trial
Patrick W. Serruys, MD, PhD, FESC; David P. Foley, MB, PhD, MRCPI, FESC;
Berthold Ho¨fling, MD, PhD, FESC; Jacques Puel, MD, FESC; Helmut D. Glogar, MD;
Ricardo Seabra-Gomes, MD, FESC; Javier Goicolea, MD; Pierre Coste, MD;
Wolfgang Rutsch, MD, FESC; Hugo Katus, MD; Hans Bonnier, MD, FESC;
William Wijns, MD, PhD, FESC; Amadeo Betriu, MD, FESC; Ulrike Hauf-Zachariou, MD, MSPM;
Eline Montauban van Swijndregt, BSc; Rein Melkert, MD; Rudiger Simon, MD, FESC;
on behalf of the EUROCARE study group
Background—In addition to its known properties as a competitive, nonselective b and a-1 receptor blocker, carvedilol
directly inhibits vascular myocyte migration and proliferation and exerts antioxidant effects that are considerably greater
than those of vitamin E or probucol. This provides the basis for an evaluation of carvedilol for the prevention of
coronary restenosis.
Methods and Results—In a prospective, double-blind, randomized, placebo-controlled trial, 25 mg of carvedilol was given
twice daily, starting 24 hours before scheduled directional coronary atherectomy and continuing for 5 months after a
successful procedure. The primary end point was the minimal luminal diameter as determined during follow-up
angiography 2662 weeks after the procedure. Of 406 randomized patients, 377 underwent attempted atherectomy, and
in 324 (88.9%), a #50% diameter stenosis was achieved without the use of a stent. Evaluable follow-up angiography
was available in 292 eligible patients (90%). No differences in minimal luminal diameter (1.9960.73 mm versus
2.0060.74 mm), angiographic restenosis rate (23.4% versus 23.9%), target lesion revascularization (16.2 versus 14.5),
or event-free survival (79.2% versus 79.7%) between the placebo and carvedilol groups were observed at 7 months.
Conclusions—The maximum recommended daily dose of the antioxidant and b-blocker carvedilol failed to reduce
restenosis after successful atherectomy. These findings are in contrast to those of the Multivitamins and Probucol Trial,
which raises doubts regarding the validity of the interpretation that restenosis reduction by probucol was via antioxidant
effects. The relationship between antioxidant agents and restenosis remains to be elucidated. (Circulation.
2000;101:1512-1518.)
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Pharmacological approaches to a reduction in restenosisafter coronary interventions using agents to prevent
vascular smooth muscle cell proliferation have been largely
ineffective.1–3 Two trials using antioxidants, one with vitamin
E4 and the other using vitamin E and probucol,5 reported a
reduction in restenosis after balloon angioplasty. This reduc-
tion initially had no mechanistic explanation,5 but a later
study suggested an inhibition of vessel remodelling as the
possible mode of action.6
Carvedilol is a nonselective b-adrenergic receptor antago-
nist with vasodilating properties that are mediated by a-1
receptor inhibition.7 It is approved for the treatment of angina
pectoris, hypertension, and heart failure. It is also a direct
inhibitor of myofibroblast migration in the vascular media
and adventitia.8,9 Significant inhibition of rat carotid intimal
hyperplasia after injury, even with acute carvedilol dosing,10
and of human pulmonary artery vascular smooth muscle cells
in culture8,9 has been reported. Furthermore, carvedilol and its
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metabolites exhibit antioxidant properties that are some 30 to
80 times more potent than vitamin E or probucol.11–13
In the EUROCARE trial, this generalized potential for
carvedilol to inhibit restenosis was evaluated in patients
undergoing successful directional coronary atherectomy
(DCA). This procedure was chosen because in 1994, DCA
was known to be more effective than balloon angioplasty, but
it was limited by a greater tendency toward restenosis.14–16
Thus, a positive outcome would enhance the clinical useful-
ness of DCA and could be generalized to other interventions.
Equally important, the trial hypothesis could be meaningfully
tested using a smaller sample size than would be required in
a population undergoing balloon angioplasty.17
Methods
Primary and Secondary End Points
The primary end point of EUROCARE was the MLD at angio-
graphic follow-up 2662 weeks after successful DCA (this was
defined by the core laboratory; see below). Secondary end points
included MACE18 at 7 months, angiographic indices of absolute and
relative loss in MLD, loss index, restenosis rate, and adverse events.
Study Population
Patients with stable or unstable angina pectoris (except Braunwald
Class 3 unstable angina) who were scheduled to undergo elective
DCA of a single native primary coronary stenosis were eligible for
inclusion. Major exclusion criteria were contraindications to carve-
dilol (eg, bradycardia ,50 bpm, second or third degree atrioventric-
ular block, obstructive airway disease, insulin-dependent diabetes,
etc) or to a discontinuation of existing b-blocker therapy, ineligibil-
ity for DCA (eg, unprotected left main stem disease and/or vessel
size ,3 mm), and planned stent implantation. Patients were also
excluded if they had a documented myocardial infarction (see
Definitions) within the preceding 5 days or intolerance to acetylsal-
icylic acid (aspirin).
Study Design
The trial was a multicenter, randomized (block size of four),
double-blind, parallel-group design. Patients were assigned to fixed
oral doses of carvedilol (25 mg BID) or placebo and, before
enrolment, were tapered off all previous antihypertensive, vasoac-
tive, and antianginal medication other than nitrates. Treatment
started a minimum of 24 hours before the scheduled DCA and was
continued for a 5-month period after successful DCA (see Defini-
tions). One month before scheduled follow-up angiography, the
study medication was tapered off over a 1-week period (12.5 mg of
carvedilol BID or placebo). During the course of the trial, antihy-
pertensive and antianginal therapy could be initiated at the discretion
of the investigators. Concomitant therapy with b-blockers,
a-blockers, anti-arrhythmics, antioxidants (eg, high-dose vitamin E
or C or probucol), antiproliferative agents (eg, cytostatics), drugs that
influence the pharmacodynamics or kinetics of carvedilol (ie, psy-
chopharmaceuticals and nonsteroidal anti-inflammatory agents, ex-
cluding aspirin and laxatives), or anticoagulants (except heparin
during the procedure) was not allowed during the trial.
Compliance was assessed by capsule counts. Trial medication was
discontinued in patients who did not have a successful DCA and in
those who experienced a MACE (except non–Q wave myocardial
infarction) or other serious adverse event. The study was conducted
in accordance with the Declaration of Helsinki and the Committee
for Proprietary Medicinal Products/Good Clinical Practice Guide-
lines. The protocol was approved by the ethics committees of all
participating centers, and all patients gave written informed consent
before inclusion.
DCA Procedure
After sheath introduction, 10 000 IU/L heparin was given; further
bolus doses were given as needed to keep an activated coagulation
time .350 s. Intravenous doses of 250 mg of acetylsalicylic acid
were also administered in patients not already taking 75 to 500 mg
daily. DCA was recommended to be guided by on-line quantitative
coronary angiography and, where possible, IVUS, with adjunctive
balloon angioplasty to achieve optimal results (see Definitions).
Angiographic Procedures and Quantitative
Coronary Angiography at the Core Laboratory
Angiographic procedures and core laboratory evaluations were
strictly standardized, as has been described in previous trials.2,3,14,16
After intracoronary nitrate bolus injection, the target stenosis was
filmed in a minimum of 2 projections before and after the procedure;
these projections were repeated identically at follow-up. The Car-
diovascular Angiographic Analysis System II (Pie Medical) was
used for the angiographic analysis at the core laboratory, using a
well-described methodology.2,3,14,16
Clinical Assessments
Patients returned for clinical follow-up visits at 1, 5, 6, and 7 months.
Shortly before reangiography, a symptom-limited exercise tolerance
test was performed. To monitor the safety of trial medication, serial
recordings of creatinine, alkaline phosphatase, g-galactosyl trans-
ferase, glutamic pyruvic transaminase, and glutamic-oxaloacetic
transaminase were assessed at each visit. Cardiac enzymes were
determined when clinically indicated and according to local practice.
Adverse events were recorded continuously, whether or not they
were considered drug-related.
Definitions
Successful DCA was defined off-line by the core laboratory as
#50% diameter stenosis; optimal DCA indicated #20% diameter
stenosis in every angiographic view, without the use of a stent or the
occurrence of a MACE, which was defined as cardiac death,
myocardial infarction, coronary artery bypass graft surgery, or
reintervention at the site of the original DCA (target lesion revascu-
larization).18 Myocardial infarction was defined as development of
new pathological Q waves and/or an increase of more than twice the
upper limit of normal of levels of creatine kinase, with concomitant
elevation of the MB fraction. Compliance with trial medication was
defined as consumption of .80% of trial medication in the first
month and .75% of medication thereafter.
Statistical Methods
Sample size calculation was based on a postulated difference in
MLD at follow-up between the placebo and carvedilol groups of
0.2060.62 mm (mean MLD: control group, 1.76 mm14 and carve-
dilol group, 1.96 mm), which is equivalent to a 30% reduction in
restenosis rate. A sample size of 152 patients per group would be
required to detect such a difference with a power of 0.80 and a
2-sided a of 0.05. To allow for nonevaluable patients, we decided to
recruit 400 total patients.
As specified in the protocol, the analysis was based on the
intention-to-treat principle; this then included all patients who took
$1 tablet of study medication, underwent successful DCA, and had
an analyzable follow-up angiogram. Safety evaluation included all
randomized patients who took $1 dose of study medication. Stu-
dent’s t test was used for intergroup comparisons of continuous
measurements, and the x2 test was used for categorical variables.
Frequency distribution curves are used to display MLD measure-
ments before and after DCA and at follow-up, and Kaplan-Meier
survival curves illustrate freedom from MACE.
Results
Procedural Results
From December 1994 to February 1997, 406 patients were
randomized to receive $1 dose of trial medication (206 took
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carvedilol and 200 took placebo). Among these, 377 under-
went attempted DCA (Figure 1). One patient died after
coronary perforation, and 5 were referred for emergency
coronary artery bypass grafting. One of these 5 patients died
perioperatively. Successful bailout stenting was performed in
29 patients.
Of the 324 patients with successful DCA (Table 1), 292
(90%) had an evaluable follow-up angiogram; these 292
patients made up the trial population. Quantitative angio-
graphic baseline and procedural parameters are shown in
Tables 2 and 3. Predilatation was performed in 6% of
patients. A 7-French device was used in 84% of cases. A
median of 13 cuts were done (interquartile range, 9 to 30),
and a maximum of 4.8 atm of balloon pressure (range, 1 to
8 atm) was applied. Postdilatation was performed in 66%
of cases using a mean balloon size of 3.6560.50 mm at a
maximal pressure of 8.263.19 mm and a balloon-to-
artery ratio of 1.0860.15 mm. An optimal result was
reported by the investigator in 68% of cases and by the
core laboratory (determined by #20% diameter stenosis)
in 26% of cases.
In the intention-to-treat population, 132 patients in the
carvedilol group (78%) and 127 in the placebo group (81.9%)
were compliant.
Figure 1. Flow chart showing derivation of the intention-to-treat population. MI indicates myocardial infarction; PTCA, percutaneous
transluminal coronary angioplasty; CABG, coronary artery bypass grafting; and DS, diameter stenosis.
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Late Outcomes
No differences in the minimal luminal diameter (MLD),
angiographic restenosis rate (Table 3 and Figure 2), or the
occurrence of major adverse cardiac events (MACE) between
the placebo and carvedilol groups were observed during a
follow-up of #7 months (Table 4 and Figure 3).
Other Adverse Events
No difference in the incidence of adverse events was ob-
served between the groups (carvedilol, 50%; placebo,
47.5%), although a higher incidence of hypotension (7.3%
versus 1%) and bradycardia (6.3% versus 0%) existed in the
carvedilol group.
Discussion
Despite the extensive in vitro and in vivo evidence for a
potential benefit of carvedilol (through the inhibition of
myofibroblast migration in the media and adventitia and of
free radical–mediated vascular inflammation and remodel-
ling, as well as its direct antiproliferative effects7–13), the
maximum recommended daily dosage failed to reduce reste-
nosis after successful DCA. Because carvedilol and its
metabolites have considerably greater antioxidant effects than
vitamin E or probucol,11–13 each of which have been reported
to reduce restenosis after balloon angioplasty,4,5 the purported
antioxidant mechanism of probucol for the observed selective
TABLE 1. Demographics and Baseline Characteristics
Carvedilol
(n5169)
Placebo
(n5155) All
Male sex 147 (87) 137 (88.4) 284 (87.7)
Age, y 57.9610.0 58.669.7 58.269.8
Smoking
Never smoked 42 (24.9) 51 (32.9) 93 (28.7)
Previous smoker 95 (56.2) 72 (46.5) 167 (51.5)
Current smoker 32 (18.9) 32 (20.6) 64 (19.8)
Diabetes mellitus 17 (10.1) 14 (9) 31 (9.6)
Hypercholesterolemia 36 (21.3) 22 (14.2) 58 (17.9)
Other hyperlipidemia 32 (18.9) 30 (19.4) 62 (19.1)
Hypertension 50 (29.6) 43 (27.7) 93 (28.7)
Previous MI 84 (49.7) 56 (36.1) 140 (43.2)
Previous PTCA 0 (0.0) 1 (0.6) 1 (0.3)
Previous CABG 0 (0.0) 4 (2.6) 4 (1.2)
Peripheral vascular disease 5 (3.0) 9 (5.8) 14 (4.3)
Medication
Calcium antagonists 40 (23.7) 50 (32.3) 90 (27.8)
ACE inhibitors 38 (22.5) 34 (21.9) 72 (22.2)
b-Blockers 105 (62.1) 97 (62.6) 202 (62.3)
Nitrates 128 (75.7) 107 (69) 235 (72.5)
Values are n (%) or mean6SD. MI indicates myocardial infarction; PTCA,
percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass
grafting; and ACE, angiotensin-converting enzyme.
TABLE 2. Baseline Angiographic Characteristics
Carvedilol
(n5169)
Placebo
(n5155)
AHA/ACC lesion type
A 12 (7.1) 11 (7.1)
B1 63 (37.5) 65 (41.9)
B2 93 (55.4) 79 (51.0)
C 0 (0.0) 0 (0.0)
No. of diseased vessels
1 140 (83.8) 125 (81.2)
2 21 (12.6) 16 (10.4)
3 6 (3.6) 13 (8.4)
Calcification 47 (27.8) 31 (20.0)
Thrombus 5 (3.0) 3 (2.0)
Lesion length, mm 8.3962.57 8.7163.04
Vessel size, mm 3.3660.56 3.4960.61
Values are n (%) or mean6SD. AHA indicates American Heart Association,
and ACC, American College of Cardiology.
TABLE 3. Acute and Follow-Up Angiographic Indices
Carvedilol
(n5154)
Placebo
(n5138)
Reference diameter, mm
Preoperative 3.3860.57 3.4860.59
Postoperative 3.5660.51 3.6160.56
Follow-up 3.2560.59 3.2060.61
MLD, mm
Preoperative 1.1960.34 1.2660.44
Postoperative 2.7760.49 2.8560.50
Follow-up* 1.9960.73 2.0060.74
Diameter stenosis, %
Preoperative 64.3369.78 63.56611.27
Postoperative 22.1967.71 20.8667.94
Follow-up† 39.13617.93 37.54618.35
Acute gain, mm 1.5860.51 1.5960.50
Late loss, mm 0.7760.70 0.8560.70
Relative loss, mm 0.2360.21 0.2560.21
Loss index 0.5160.49 0.5560.48
Restenosis rate, % 23.4 23.9
Values are mean6SD, unless otherwise indicated.
*P50.92; †P50.46.
Figure 2. Cumulative frequency curves of MLD before (PRE)
and after (POST) successful DCA and at follow-up (F-UP). Mean
values (6SD) are on the right, and median values are next to the
curves. CUM indicates cumulative; ITT, intention-to-treat; and
ANG, angiographic.
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benefit in the Multivitamins and Probucol Trial in Prevention
of Restenosis Post Percutaneous Coronary Angiography
seems putative.6 On the basis of the neutral outcome of this
trial, we think that in the probucol trial, either another
mechanism was responsible for the observed reduction in
renarrowing or the outcome was serendipitous. In addition, it
must be concluded that the role of systemic antioxidants for
the prevention of restenosis is debatable and must be further
elucidated.
The question arises as to why no effect was observed in this
multicenter clinical trial of an agent that has greater antiox-
idant effects than probucol11–13 in addition to its other listed
effects.7–10 First, although it may be claimed that the rat
model is not an ideal in vivo platform for a clinical trial, this
trial hypothesis was based on the combined evidence from
many other studies,7–13 as well as the acceptability of this
drug for clinical use.
Adequacy of Dose and Pretreatment Period
Carvedilol reaches peak plasma levels 2 hours after an oral
dose of 25 mg, and steady-state plasma levels are achieved
after 5 half-lives of ’7 hours each,7 which is a 35-hour
period. In this trial, for practical purposes, patients were
pretreated for a minimum of 24 hours, undergoing DCA
within 2 hours after taking the third dose of trial medication.
Thus, although a steady-state plasma level of carvedilol may
not yet have been reached in all patients, DCA was usually
performed to coincide with peak plasma levels, and carvedilol
accumulates rapidly in the lipid environment, including cell
membranes and the lipid moiety of lipoproteins.7,19 In a trial
that used a dose regimen similar to that of this trial, 84%
suppression of neointimal hyperplasia was observed in the rat
carotid artery balloon angioplasty model, with pretreatment
for only 2 hours before and 14 days after balloon angio-
plasty.10 Additionally, protection by carvedilol from oxygen
free-radical–induced damage has been demonstrated at con-
centrations that are consistent with the plasma levels of the
drug attained in patients on a dose of 25 to 50 mg a day (ie,
100 to 300 nmol/L).13 Furthermore, clinical studies have
recently demonstrated that carvedilol creates a marked reduc-
tion in low-density lipoprotein oxidation in hypertensive
patients19 and helps stop the development of nitrate tolerance,
which is associated with superoxide anion production.20
Thus, it can be assumed that the pretreatment and dose
regimen should have been sufficient to reproduce, in humans,
the experimental effects observed in vitro and in animals.
It is also important to note that the trial medication was
safe; no differences between groups existed in the incidence
of adverse events, except hypotension and bradycardia. This
led to discontinuation of carvedilol in only 3.9% of patients,
which is not untoward given that carvedilol is a vasodilating
b-blocker.
Appropriateness of DCA-Treated Patients for
This Trial
At the time this trial was planned, it was known that DCA
achieved greater acute results but was limited by a greater
tendency toward renarrowing when compared with conven-
tional balloon angioplasty.14–16 Stenting was in the early
phase of clinical evaluation: the Belgian Netherlands Stent
Study (BENESTENT) and Stent Restneosis Study (STRESS)
had not yet been completed; thus, stenting was only per-
formed as a bailout procedure, which indicated a failed DCA.
The mean luminal loss observed after DCA by the core
laboratory was 0.81 mm,14,16 which is .2 times the average
after balloon angioplasty.2,3,14,16 Before intravascular ultra-
sound (IVUS) studies, which changed our perception of
restenosis,21–23 we assumed this renarrowing was due to
neointimal hyperplasia.24 For this reason, the investigation of
an agent with antioxidant, antichemotactic, and direct anti-
proliferative effects seemed ideally suited to an atherectomy-
treated patient population. IVUS studies have since demon-
strated that vessel remodelling may account for .50% of the
luminal renarrowing response after DCA,21,22 which reduces
the target for antiproliferative drugs. However, if the report
by Coˆte´ et al6 on probucol is correct, the antioxidant effects
of carvedilol should have the potential to inhibit vascular
remodelling as well as inflammation such that a general
reduction of the response to injury could have been reason-
ably expected.7–13,19,20
Because the pretreatment and dose regimen used seems
adequate, it can only be speculated that the many alternative
pathway cascades that lead to vascular remodelling and
neointimal hyperplasia have the capacity to overcome spe-
TABLE 4. MACE in Each Group at 7-Month Follow-Up
Carvedilol
(n5169)
Placebo
(n5155)
Death 0 (0.0) 2 (1.3)
MI 5 (3.0) 5 (3.2)
Q wave MI 1 (0.6) 0 (0.0)
Non-Q Wave MI 4 (2.4) 5 (3.2)
CABG 3 (1.8) 3 (1.9)
Re-PTCA (TLR) 26 (15.4) 24 (15.5)
No MACE 135 (79.9)* 121 (78.1)*
Values are n (%). MI indicates myocardial infarction; CABG, coronary artery
bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; and
TLR, target lesion revascularization.
*P50.64 by Wilcoxon rank sums text at 240 days.
Figure 3. Kaplan-Meier estimates of freedom from death, myo-
cardial infarction (MI), coronary artery bypass grafting (CABG),
and repeat angioplasty (Re-PTCA). LR indicates log ranking;
F(E), Fischer exercise test; and RR, relative risk.
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cific inhibitory agents to achieve what is essentially an
effective natural wound healing response.23
Comparison of Atherectomy Results With
Other Trials
Although the present study is not a trial asserting the specific
value of atherectomy (because DCA is now used in ,2% of
patients undergoing percutaneous therapies), it is appropriate
to compare the short- and long-term results with those of
other trials. Procedural success was obtained in 88.9% of
cases, as compared with 92% in the Balloon versus Optimal
Atherectomy Trial (BOAT).25 The MLD after the procedure
was 2.81 mm in this trial and 2.82 mm in BOAT; in the
subgroup of patients with “optimal atherectomy,” the MLD
after the procedure was 3.09 mm in this trial compared with
3.16 mm in the Optimal Atherectomy Restenosis Study
(OARS).26 The late loss (0.81 mm) in EUROCARE was
substantially less than that in both BOAT (0.96 mm) and
OARS (1.18 mm), so the restenosis rate in EUROCARE is
also lower (23.6%) than that in BOAT (31.4%) and OARS
(28.9%). The incidence of target lesion revascularization in
EUROCARE (17.1%) was slightly lower than that in BOAT
(21.1%) and similar to that in OARS (17.8%). Thus, the level
of intervention by DCA that was performed in this trial was
representative of the concurrent best clinical practice, and an
adequate platform was created for testing an anti-restenosis
strategy.
Limitations
Because this was an atherectomy study, it would have been
ideal to have IVUS guidance; however, in 1994, IVUS was
not yet widely used and, given the lack of difference in
outcome between the groups, it would not have changed the
outcome of the trial. Also, the antioxidant activity of carve-
dilol was not measured in this trial because the previously
accumulated specific studies of antioxidant effects7–10,20,21
were considered sufficient evidence to assume a greater
clinical effect in this regard than vitamin E or probucol.
Conclusions
Carvedilol was safe and well tolerated by patients undergoing
DCA, both during the procedure and in the follow-up period.
Despite extensive evidence depicting its potent antioxidant,
antichemotactic, and antiproliferative effects, the maximum
recommended daily dosage failed to demonstrate any reduc-
tion in restenosis as measured by quantitative angiographic
and clinical parameters. These results question the validity of
the explanation that the reported reduction in restenosis by
probucol in the Multivitamins and Probucol Trial was via
antioxidant mechanisms. The relationship between antioxi-
dant agents and restenosis remains to be elucidated.
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